Literature DB >> 29530850

Posaconazole-Induced Pseudohyperaldosteronism.

Kevin Kuriakose1, Whitney J Nesbitt2, Matthew Greene3, Bryan Harris3.   

Abstract

A woman in her late 60s with disseminated histoplasmosis was treated with posaconazole because first-line therapies were not tolerated. She subsequently presented with decompensated heart failure, hypertension, and hypokalemia. Laboratory tests revealed low renin and aldosterone levels. A potential mechanism is inhibition of the enzyme 11β-hydroxysteroid dehydrogenase 2, with resultant apparent mineralocorticoid excess.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  aldosterone; hypertension; hypokalemia; mineralocorticoid; posaconazole; pseudohyperaldosteronism

Mesh：

Substances：

Year:  2018        PMID： 29530850      PMCID： PMC5923153          DOI： 10.1128/AAC.02130-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

Authors:  Aline H Saad; Daryl D DePestel; Peggy L Carver
Journal:  Pharmacotherapy       Date:  2006-12       Impact factor: 4.705

2.  Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.

Authors:  Maryam Mahmood; Omar Abu Saleh; M Rizwan Sohail
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.

Authors:  James Kim; Jean Y Tang; Ruoyu Gong; Jynho Kim; John J Lee; Karl V Clemons; Curtis R Chong; Kris S Chang; Mark Fereshteh; Dale Gardner; Tannishtha Reya; Jun O Liu; Ervin H Epstein; David A Stevens; Philip A Beachy
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

4.  In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia.

Authors:  George R Thompson; Diana Chang; Rebecca R Wittenberg; Ian McHardy; Alison Semrad
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole.

Authors:  Katharina R Beck; Murielle Bächler; Anna Vuorinen; Sandra Wagner; Muhammad Akram; Ulrich Griesser; Veronika Temml; Petra Klusonova; Hideaki Yamaguchi; Daniela Schuster; Alex Odermatt
Journal:  Biochem Pharmacol       Date:  2017-01-25       Impact factor: 5.858

6.  Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Authors:  Rafael F Duarte; Javier López-Jiménez; Oliver A Cornely; Michel Laverdiere; David Helfgott; Shariq Haider; Pranatharthi Chandrasekar; Amelia Langston; John Perfect; Lei Ma; Marlou L P S van Iersel; Nancy Connelly; Nicholas Kartsonis; Hetty Waskin
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

7.  Role of itraconazole metabolites in CYP3A4 inhibition.

Authors:  Nina Isoherranen; Kent L Kunze; Kyle E Allen; Wendel L Nelson; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2004-07-08       Impact factor: 3.922

8.  Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.

Authors:  D Wexler; R Courtney; W Richards; C Banfield; J Lim; M Laughlin
Journal:  Eur J Pharm Sci       Date:  2004-04       Impact factor: 4.384

9.  Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.

Authors:  Lydia M M Vermeer; Caleb D Isringhausen; Brian W Ogilvie; David B Buckley
Journal:  Drug Metab Dispos       Date:  2015-12-14       Impact factor: 3.922

10.  Suspected posaconazole toxicity in a pediatric oncology patient.

Authors:  Jessica Martino; Brian T Fisher; Kristopher R Bosse; Rochelle Bagatell
Journal:  Pediatr Blood Cancer       Date:  2015-05-06       Impact factor: 3.167
View more
  7 in total

1.  Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis.

Authors:  Huan-Huan Ji; Xue-Wen Tang; Ni Zhang; Ben-Nian Huo; Ying Liu; Lin Song; Yun-Tao Jia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

2.  Posaconazole-Induced Hypertension Masquerading as Congenital Adrenal Hyperplasia in a Child with Cystic Fibrosis.

Authors:  Neha Agarwal; Louise Apperley; Norman F Taylor; David R Taylor; Lea Ghataore; Ellen Rumsby; Catherine Treslove; Richard Holt; Rebecca Thursfield; Senthil Senniappan
Journal:  Case Rep Med       Date:  2020-08-28

3.  Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism.

Authors:  Minh-Vu H Nguyen; Matthew R Davis; Rebecca Wittenberg; Ian Mchardy; John W Baddley; Brian Y Young; Alex Odermatt; George R Thompson
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

Review 4.  Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients.

Authors:  Megan E Klatt; Gregory A Eschenauer
Journal:  J Fungi (Basel)       Date:  2021-01-22

5.  Blastomycosis Presenting With Acute Airway Obstruction From a Retropharyngeal Abscess and Complicated by Severe Hypokalemia During Posaconazole Therapy: A Case Report and Review of Literature.

Authors:  John J Hanna; Jessica M Guastadisegni; Marcus A Kouma; Emily B Knez; Reuben J Arasaratnam; Donald F Storey
Journal:  Open Forum Infect Dis       Date:  2022-08-11       Impact factor: 4.423

6.  Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole.

Authors:  Maria Dolores Sanchez-Niño; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2018-09-20

7.  High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Authors:  Alexander F A D Schauwvlieghe; Jochem B Buil; Paul E Verweij; Rogier A S Hoek; Jan J Cornelissen; Nicole M A Blijlevens; Stefanie S V Henriet; Bart J A Rijnders; Roger J M Brüggemann
Journal:  Mycoses       Date:  2019-12-15       Impact factor: 4.377
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.